Full course description
The Special Education Law chapter offers a comprehensive overview of key legal frameworks impacting students with disabilities. Topics include historical case law, IEP/IFSP basics, Maryland-specific protections, and specialized services like home and hospital teaching. Advanced levels address bullying, COVID-19 compensatory services, and dispute resolution processes. This chapter equips professionals with practical insights to navigate legal aspects of special education, fostering an informed and supportive approach to advocacy and service provision.
The Special Education Law Chapter spans 12 topics across four levels of instruction. Levels 1 and 2 provide foundational knowledge beneficial for medical professionals and allied professionals, including educators, social workers, therapists, and psychologists.
Levels 3 to 4 shift to a more clinical focus, offering advanced insights geared toward medical doctors and sub-specialists.
The table below outlines the complete chapter content.
Chapter Editor
Mary Leppert, MB, BCH is a neurodevelopmental pediatrician in the Department of Neurology and Developmental Medicine at Kennedy Krieger Institute. Dr. Leppert is also the Division Director of Developmental Pediatrics in the Department of Pediatrics at Johns Hopkins University School of Medicine. Dr. Leppert's focus is on the education on neurodevelopmental disorders. She is the founder and director of the Teaching Excellence in Neuro Development (TEND) program, the director of Kennedy Krieger Project ECHO and is the chief editor of the Kennedy Krieger Instruction in Neurodevelopmental Disorders (KIND) curriculum. In addition, Dr. Leppert is an associate professor of pediatrics at the Johns Hopkins University School of Medicine.
Content, Featured Experts, and Learner Groups
Level |
Topic Content |
Featured Expert |
Learner Group(s) |
Level 1 |
1.1 History of Disability and Education Case Law |
Selene Almazan, Esq. |
Allied professionals Medical Professionals Sub-Specialist Professionals |
1.2 Defining Special Education |
Mallory Legg, Esq. |
||
1.3 IFSP & IEP |
Mallory Legg, Esq. |
||
Level 2 |
2.1 Additional Legal Protections in MD (Maryland Distinctions in Special Education Law) |
Alyssa Navarrete Thorn, Esq. |
Allied professionals Medical Professionals Sub-Specialist Professionals |
2.2 FBAs and BIPs |
Mallory Legg, Esq. |
||
2.3 Extended School Year |
Alyssa Navarrete Thorn, Esq. |
||
2.4 Home and Hospital Teaching |
Mallory Legg, Esq. |
||
Level 3 |
3.1 Bullying, Harassment & Intimidation of Students with Disabilities |
Maureen Van Stone, Esq., MS |
Medical Professionals Sub-Specialist Professionals |
3.2 Compensatory Education/ Recovery Services During the COVID-19 Pandemic |
Mallory Legg, Esq. |
||
Level 4 |
4.1 Dispute Resolution: Informal Options |
Mallory Legg, Esq. |
Medical Professionals Sub-Specialist Professionals |
4.2 Dispute Resolution: Formal Options |
Mallory Legg, Esq. |
||
4.3 MD Due Process Hearing Data |
Mallory Legg, Esq. |
What is the KIND Curriculum?
Terms of Use & Privacy Policy
The Learning Materials are intended only to provide general information and need to be adapted for individualized patient care based on each practitioners’ professional judgment, unique patient circumstances, and other pertinent factors. The Learning Materials are not intended to constitute general medical advice or treatment or advice or treatment for any particular patient. The Learning Materials are not intended to create a doctor-patient relationship between/among Kennedy Krieger Institute, its physicians and individual patients or their family members or caregivers. Kennedy Krieger Institute makes no warranty, expressed or implied, with respect to the currency, completeness, applicability, or accuracy of the Learning Materials. To the extent that the Learning Materials include information regarding drug dosing, every effort will be made to identify when drug or medical device information included in the Learning Materials is not in agreement with FDA approval or guidance. However, it is the responsibility of the practitioner to ascertain FDA dosing recommendations and approval status of prescribed drugs and devices in their clinical practices.
The Learning Materials are protected by copyright laws and in some cases patent laws, and all rights are reserved under such laws. No part of the Learning Materials may be reproduced in any form by any means, or utilized in any other way, absent prior written permission from the copyright owner. |